
Ambry Genetics Upgrades Breast Cancer Risk Tool to Include Breast Density
Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. and long recognized as a pioneer in clinical genomic testing, has announced a significant enhancement to its Ambry CARE Program® (CARE). The program, a digital platform designed to streamline…








